Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After or Does Not Respond to Treatment
Conditions: Recurrent Mycosis Fungoides; Recurrent Mycosis Fungoides and Sezary Syndrome; Refractory Mycosis Fungoides; Refractory Mycosis Fungoides and Sezary Syndrome; Sezary Syndrome; Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage II Mycosis Fungoides and S ezary Syndrome AJCC v8; Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8; Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8 Interventions: Biological: Magrolimab; Biological: Mogamulizumab Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Cutaneous T cell lymphoma | Lymphoma | Mycosis Fungoides | Research | Sezary Syndrome